Angiogenesis: Basic Mechanisms and Clinical Applications

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 3, 2003, Pages 253-280

  Chhokar, Vikram ^a   Tucker, Amy L ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEINASE; SCATTER FACTOR; STRUCTURAL PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; ISCHEMIA; MESENCHYME; NEOPLASM; PATIENT SELECTION; REPRODUCTION; REVIEW; TUMOR CELL; TUMOR GROWTH; WOUND HEALING;

EID: 0242694465     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320300700304     Document Type: Review

References (240)

1. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997.
2. Asahara T, Takahashi T, Masuda H, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972, 1999.
3. Crosby JR, Kaminski WE, Schatteman G, et al: Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87:728-730, 2000.
4. Walter DH, Rittig K, Bahlmann FH, et al: Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circ 105:3017-3024, 2002.
5. Shi Q, Rafii S, Wu MH, Wijelath ES, et al: Evidence for circulating bone marrow-derived endothelial cells. Blood 92:362-367, 1998.
6. Takahashi T, Kalka C, Masuda H, et al: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999.
7. Jackson KA, Majka SM, Wang H, et al: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107:1395-1402, 2001.
8. Kocher AA, Schuster MD, Szabolcs MJ, et al: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-436, 2001.
9. Lyden D, Hattori K, Dias S, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201, 2001.
10. Bikfalvi A, Bicknell R: Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. TiPS 23:576-582, 2002.
11. Semenza GL: HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:1474-1480, 2000.
12. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54, 2001.
13. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472, 2001.
14. Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Ann Rev Mede 54:17-28, 2003.
15. Semenza GL: Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease. Pediatr Res 49:614-617, 2001.
16. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999.
17. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741, 2000.
18. Buschmann I, Schaper W: Arteriogenesis versus angiogenesis: Two mechanisms of vessel growth. News Physiol Society 14:121-125, 1999.
19. Feoktistov I, Ryzhov S, Goldstein AE, et al: Mast cell-mediated stimulation of angiogenesis: Cooperative interaction between A2B and A3 adenosine receptors. Circ Res 92:485-492, 2003.
20. Grant MB, Tarnuzzer RW, Caballero S, et al: Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res 85:699-706, 1999.
21. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al: Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol 160:2231-2244, 2002.
22. Patterson C, Perrella MA, Endege WO, et al: Down-regulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 98:490-496, 1996.
23. Hayakawa Y, Takeda K, Yagita H, et al: IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100:1728-1733, 2002.
24. Coughlin CM, Salhany KE, Gee MS: Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25-34, 1998.
25. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, et al: Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 164:217-222, 2000.
26. Lee H, Goetzl EJ, An S: Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am J Physiol-Cell Physiol 278:C612-C618, 2000.
27. Bernardini G, Ribatti D, Spinetti G, et al: Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83-101, 2003.
28. Pepper MS, Ferrara N, Orci L, et al: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Comm 181:902-906, 1991.
29. Mandriota SJ, Seghezzi G, Vassalli JD, et al: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270:9709-9716, 1995.
30. Carmeliet P, Ng YS, Nuyens D, et al: Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495-502, 1999.
31. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996.
32. Enholm B, Paavonen K, Ristimaki A, et al: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14:2475-2483, 1997.
33. Veikkola T, Alitalo K: VEGFs, receptors and angiogenesis. Sem Cancer Biol 9:211-220, 1999.
34. Plate KH, Breier G, Millauer B, et al: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827, 1993.
35. Jiang Y, Jahagirdar BN, Reinhardt RL, et al: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49, 2002.
36. Barleon B, Sozzani S, Zhou D, et al: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343, 1996.
37. Fong GH, Rossant J, Gertsenstein M, et al: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995.
38. Cao Y, Linden P, Shima D, et al: In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 98:2507-2511, 1996.
39. Huang K, Andersson C, Roomans GM, et al: Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int J Biochem Cell Biol 33:315-324, 2001.
40. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Science's Stke [Electronic Resource]: Signal Transduction Knowledge Environment 2001:RE21, 2001.
41. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995.
42. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362, 1999.
43. Takahashi T, Yamaguchi S, Chida K, et al: A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20:2768-2778, 2001.
44. Fujio Y, Walsh K: Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349-16354, 1999.
45. Dimmeler S, Fleming I, Fisslthaler B, et al: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605, 1999.
46. Detmar M, Brown LF, Schon MP, et al: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111:1-6, 1998.
47. Thurston G, Suri C, Smith K, et al: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514, 1999.
48. Chavakis E, Dimmeler S: Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 22:887-893, 2002.
49. Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169, 1996.
50. Suri C, Jones PF, Patan S, et al: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996.
51. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997.
52. Valenzuela DM, Griffiths JA, Rojas J, et al: Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96:1904-1909, 1999.
53. Wong AL, Haroon ZA, Werner S, et al: Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567-574, 1997.
54. Loughna S, Sato TN: Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 20:319-325, 2001.
55. Korhonen J, Polvi A, Partanen J, et al: The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis [erratum appears in Oncogene 1996 Feb 15;12(4):943]. Oncogene 9:395-403, 1994.
56. Korhonen J, Polvi A, Partanen J, et al: The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis [erratum appears in Oncogene 1996 Feb 15;12(4):943]. Oncogene 9:395-403, 1994.
57. Korhonen J, Lahtinen I, Halmekyto M, et al: Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood 86:1828-1835, 1995.
58. Kim I, Kim HG, So JN, et al: Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86:24-29, 2000.
59. Jones N, Dumont DJ: The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 17:1097-1108, 1998.
60. Dumont DJ, Gradwohl G, Fong GH, et al: Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8:1897-1909, 1994.
61. Sato TN, Tozawa Y, Deutsch U, et al: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74, 1995.
62. Dow JK, deVere White RW: Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 55:800-806, 2000.
63. Grines CL, Watkins MW, Helmer G, et al: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297, 2002.
64. Ornitz DM: FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22:108-112, 2000.
65. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, et al: Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16:268-271, 1991.
66. Nakamura T, Mochizuki Y, Kanetake H, et al: Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem Biophys Res Comm 289:801-806, 2001.
67. Javerzat S, Auguste P, Bikfalvi A: The role of fibroblast growth factors in vascular development. Trends Mol Med 8:483-489, 2002.
68. Presta M, Moscatelli D, Joseph-Silverstein J, et al: Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 6:4060-4066, 1986.
69. Bikfalvi A, Klein S, Pintucci G, et al: Biological roles of fibroblast growth factor-2. Endocr Rev 18:26-45, 1997.
70. Matsumoto T, Turesson I, Book M, et al: p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 156:149-160, 2002.
71. Ong SH, Hadari YR, Gotoh N, et al: Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA 98:6074-6079, 2001.
72. Cross MJ, Hodgkin MN, Roberts S, et al: Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J Cell Science 113:643-651, 2000.
73. Wu LW, Mayo LD, Dunbar JD, et al: Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275:5096-5103, 2000.
74. Deng CX, Wynshaw-Boris A, Shen MM, et al: Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 8:3045-3057, 1994.
75. Xu X, Weinstein M, Li C, et al: Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development 125:753-765, 1998.
76. Colvin JS, Bohne BA, Harding GW, et al: Skeletal over-growth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397, 1996.
77. Lee SH, Schloss DJ, Swain JL: Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 275:33679-33687, 2000.
78. Pintucci G, Moscatelli D, Saponara F, et al: Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 16:598-600, 2002.
79. Ortega S, Ittmann M, Tsang SH, et al: Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA 95:5672-5677, 1998.
80. Nakamura T, Nawa K, Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Comm 122:1450-1459, 1984.
81. Gohda E, Tsubouchi H, Nakayama H, et al: Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 81:414-419, 1988.
82. Strain AJ, Ismail T, Tsubouchi H, et al: Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest 87:1853-1857, 1991.
83. Matsumoto K, Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 119:591-600, 1996.
84. Rosen EM, Goldberg ID, Kacinski BM, et al: Smooth muscle releases an epithelial cell scatter factor which binds to heparin. In Vitro Cell Dev Biol 25:163-173, 1989.
85. Stoker M, Perryman M: An epithelial scatter factor released by embryo fibroblasts. J Cell Science 77:209-223, 1985.
86. Nakamura Y, Morishita R, Higaki J, et al: Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: Additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 14:1067-1072, 1996.
87. Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251:802-804, 1991.
88. Naldini L, Vigna E, Narsimhan RP, et al: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6:501-504, 1991.
89. Furge KA, Zhang YW, Vande Woude GF: Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene 19:5582-5589, 2000.
90. Sengupta S, Gherardi E, Sellers LA, et al: Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69-75, 2003.
91. Van Belle E, Witzenbichler B, Chen D, et al: Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis. Circ 97:381-390, 1998.
92. Xin X, Yang S, Ingle G, et al: Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158:1111-1120, 2001.
93. Eliceiri BP, Cheresh DA: The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227-1230, 1999.
94. Brooks PC, Stromblad S, Sanders LC, et al: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693, 1996.
95. Petitclerc E, Stromblad S, von Schalscha TL, et al: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59:2724-2730, 1999.
96. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502, 1995.
97. Brooks PC. Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev 15:187-194, 1996.
98. Koch AE, Halloran MM, Haskell CJ, et al: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519, 1995.
99. Nguyen M, Strubel NA, Bischoff J: A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365:267-269, 1993.
100. Labow MA, Norton CR, Rumberger JM, et al: Characterization of E-selectin-deficient mice: Demonstration of overlapping function of the endothelial selectins. Immunity 1:709-720, 1994.
101. Carmeliet P, Lampugnani MG, Moons L, et al: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 99:147-157, 1999.
102. Carmeliet P, Collen D: Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann NY Acad Sci 902:249-262, 2000.
103. Corada M, Zanetta L, Orsenigo F, et al: A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100:905-911, 2002.
104. Pepper MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21:1104-1117, 2001.
105. Montesano R, Pepper MS, Mohle-Steinlein U, et al: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435-445, 1990.
106. Rabbani SA, Mazar AP: The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10:393-415, 2001.
107. Ingber DE: Tensegrity: The architectural basis of cellular mechanotransduction. Ann Rev Physiol 59:575-599, 1997.
108. Blasi F: uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:415-417, 1997.
109. Murphy G, Stanton H, Cowell S, et al: Mechanisms for pro matrix metalloproteinase activation. APMIS 107:38-44, 1999.
110. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424, 1994.
111. Ploplis VA, Carmeliet P, Vazirzadeh S, et al: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92:2585-2593, 1995.
112. Romer J, Bugge TH, Pyke C, et al: Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 2:287-292, 1996.
113. Soff GA, Sanderowitz J, Gately S, et al: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96:2593-2600, 1995.
114. Heymans S, Luttun A, Nuyens D, et al: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5:1135-1142, 1999.
115. Liekens S, De Clercq E, Neyts J: Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61:253-270, 2001.
116. Grossfeld GD, Ginsberg DA, Stein JP, et al: Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Nat Cancer Instit 89:219-227, 1997.
117. Streit M, Velasco P, Brown LF, et al: Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155:441-452, 1999.
118. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994.
119. Colman RW, Jameson BA, Lin Y, et al: Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95:543-550, 2000.
120. Rhim TY, Park CS, Kim E, et al: Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Comm 252:513-516, 1998.
121. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928, 1999.
122. Fukao H, Ueshima S, Okada K, et al: The role of the pericellular fibrinolytic system in angiogenesis. Jap J Physiol 47:161-171, 1997.
123. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994.
124. Ingber DE: Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 91:877-887, 2002.
125. Lindahl P, Hellstrom M, Kalen M, et al: Endothelial-perivascular cell signaling in vascular development: Lessons from knockout mice. Curr Opin Lipidol 9:407-411, 1998.
126. Himanen JP, Nikolov DB: Eph signaling: A structural view. Trends Neurosci 26:46-51, 2003.
127. Dodelet VC, Pasquale EB: Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis. Oncogene 19:5614-5619, 2000.
128. Pepper MS: Manipulating angiogenesis. From basic science to the bedside. Arterioscler ThrombVasc Biol 17:605-619, 1997.
129. Ito WD, Arras M, Winkler B, et al: Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80:829-837, 1997.
130. Iba O, Matsubara H, Nozawa Y, et al: Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 106:2019-2025, 2002.
131. Brown LF, Tognazzi K, Dvorak HF, et al: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148:1065-1074, 1996.
132. Lee RJ, Springer ML, Blanco-Bose WE, et al: VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102:898-901, 2000.
133. Roivainen M, Viik-Kajander M, Palosuo T, et al: Infections, inflammation, and the risk of coronary heart disease. Circulation 101:252-257, 2000.
134. Edelman ER, Mathiowitz E, Langer R, et al: Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12:619-626, 1991.
135. Ortega S, Schaeffer MT, Soderman D, et al: Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. J Biol Chem 266:5842-5846, 1991.
136. Tse HF, Kwong YL, Chan JK, et al: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361:47-49, 2003.
137. Banai S, Shweiki D, Pinson A, et al: Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis. Cardiovasc Res 28:1176-1179, 1994.
138. Hashimoto E, Ogita T, Nakaoka T, et al: Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 267:H1948-H1954, 1994.
139. Cohen MV, Vernon J, Yaghdjian V, et al: Longitudinal changes in myocardial basic fibroblast growth factor (FGF-2) activity following coronary artery ligation in the dog. J Mol Cell Cardiol 26:683-690, 1994.
140. Giordano FJ, Ping P, McKirnan MD, et al: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534-539, 1996.
141. Mack CA, Patel SR, Schwarz EA, et al: Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168-176, 1998.
142. Zhang D, Gai L, Fan R, et al: Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165. Chin Med J 115:643-648, 2002.
143. Tanaka E, Hattan N, Ando K: Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits. J Thorac Cardiovasc Surg 120:720-728, 2000.
144. Fuchs S, Baffour R, Zhou YF, et al: Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 37:1726-1732, 2001.
145. Schumacher B, Pecher P, von Specht BU, et al: Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 97:645-650, 1998.
146. Laham RJ, Sellke FW, Edelman ER, et al: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100:1865-1871, 1999.
147. Rosengart TK, Lee LY, Patel SR, et al: Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468-474, 1999.
148. Symes JF, Losordo DW, Vale PR, et al: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830-836, 1999.
149. Henry TD, Annex BH, McKendall GR, et al: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107:1359-1365, 2003.
150. Simons M, Annex BH, Laham RJ, et al: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105:788-793, 2002.
151. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. Trans-Atlantic Inter-Society Concensus (TASC). J Vascular Surg 31:S1-S296, 2000.
152. Rissanen TT, Vajanto I, Yla-Herttuala S: Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb on the way to the clinic. Eur J Clin Invest 31:651-666, 2001.
153. Springer ML, Chen AS, Kraft PE, et al: VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol Cell 2:549-558, 1998.
154. Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999.
155. Yamashita J, Itoh H, Hirashima M, et al: Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408:92-96, 2000.
156. Kawamoto A, Gwon HC, Iwaguro H, et al: Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103:634-637, 2001.
157. Kamihata H, Matsubara H, Nishiue T, et al: Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 22:1804-1810, 2002.
158. Asahara T, Bauters C, Zheng LP, et al: Synergistic effect of vascular endothelial growth factor and basic-fibroblast growth factor on angiogenesis in vivo. Circulation 92:11365-11371, 1995.
159. Chae JK, Kim I, Lim ST, et al: Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscl Thromb Vasc Biol 20:2573-2578, 2000.
160. Vincent KA, Shyu KG, Luo Y, et al: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-lalpha/VP16 hybrid transcription factor. Circulation 102:2255-2261, 2000.
161. Baumgartner I, Pieczek A, Manor O, et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia Circulation 97:1114-1123, 1998.
162. Lazarous DF, Unger EF, Epstein SE, et al: Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial. J Am Coll Cardiol 36:1239-1244, 2000.
163. Laitinen M, Makinen K, Manninen H, et al: Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9:1481-1486, 1998.
164. Makinen, K, Laitinen, M, Manninen, H, et al: Catheter-mediated gene transfer to human lower limb arteries. Circulation 100:I-770, 2000 (abstr).
165. Lederman RJ, Mendelsohn FO, Anderson RD, et al: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359:2053-2058, 2002.
166. Nakata N, Kato H, Kogure K, et al: Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil. Brain Res 605:354-356, 1993.
167. Puumala M, Anderson RE, Meyer FB: Intraventricular infusion of HBGF-2 promotes cerebral angiogenesis in Wistar rat. Brain Res 534:283-286, 1990.
168. Lee RJ, Springer ML, Blanco-Bose WE, et al: VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102:898-901, 2000.
169. Baumgartner I, Rauh G, Pieczek A, et al: Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Int Med 132:880-884, 2000.
170. Horowitz JR, Rivard A, van der Zee R, et al: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17:2793-2800, 1997.
171. Thurston G, Rudge JS, Ioffe E, et al: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460-463, 2000.
172. Mazue G, Bertolero F, Jacob C, et al: Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann NY Acad Sci 638:329-340, 1991.
173. Dvorak HF, Nagy JA, Feng D, et al: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97-132, 1999.
174. Elson DA, Thurston G, Huang LE, et al: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 15:2520-2532, 2001.
175. Li J, Post M, Volk R, et al: PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55, 2000.
176. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906-3927, 2002.
177. Kandel J, Bossy-Wetzel E, Radvanyi F, et al: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991.
178. Gomez-Navarro J, Contreras JL, Arafat W, et al: Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 7:43-52, 2000.
179. Holash J, Maisonpierre PC, Compton D, et al: Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999.
180. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000.
181. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
182. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999.
183. Brower V: Tumor angiogenesis-new drugs on the block. Nat Biotechnol 17:963-968, 1999.
184. Weng DE, Usman N: Angiozyme: A novel angiogenesis inhibitor. Curr Oncol Rep 3:141-146, 2001.
185. Sandberg JA, Parker VP, Blanchard KS, et al: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 40:1462-1469, 2000.
186. Wellstein A, Czubayko F: Inhibition of fibroblast growth factors. Breast Cancer Res Treat 38:109-119, 1996.
187. Doebler JA: Blockade of sulfur mustard cytotoxicity in human epidermal keratinocytes with the purinergic receptor antagonist suramin. Vet Hum Toxicol 45:14-17, 2003.
188. Takano S, Gately S, Neville ME, et al: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654-2660, 1994.
189. Kuyu H, Lee WR, Bare R, et al: Recent advances in the treatment of prostate cancer. Ann Oncol 10:891-898, 1999.
190. Small EJ, Halabi S, Ratain MJ, et al: Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol 20:3369-3375, 2002.
191. Calvo E, Cortes J, Rodriguez J, et al: Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter phase II study. Cancer 92:2435-2443, 2001.
192. Firsching A, Nickel P, Mora P, et al: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55:4957-4961, 1995.
193. Laird AD, Vajkoczy P, Shawver LK, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000.
194. Cherrington JM, Strawn LM, Shawver LK: New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res 79:1-38, 2000.
195. Vesikari T, Nuutila A, Cantell K: Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 77:619-622, 1988.
196. Sampaio EP, Kaplan G, Miranda A, et al: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168:408-414, 1993.
197. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085, 1994.
198. Dredge K, Dalgliesh AG, Marriott JB: Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14:331-335, 2003.
199. Richardson P, Hideshima T, Anderson K: Thalidomide in multiple myeloma. Biomed Pharmacother 56:115-128, 2002.
200. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997.
201. Moser TL, Stack MS, Asplin I, et al: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96:2811-2816, 1999.
202. Troyanovsky B, Levchenko T, Mansson G, et al: Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247-1254, 2001.
203. Tarui T, Miles LA, Takada Y: Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 276:39562-39568, 2001.
204. Claesson-Welsh L, Welsh M, Ito N, et al: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 95:5579-5583, 1998.
205. Scappaticci FA, Contreras A, Smith R, et al: Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis 4:263-268, 2001.
206. Antoine N, Greimers R, De Roanne C, et al: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54:2073-2076, 1994.
207. Yoshida A, Anand-Apte B, Zetter BR: Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13:57-64, 1996.
208. Turk BE, Griffith EC, Wolf S, et al: Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 6:823-833, 1999.
209. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al: Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 16:1444-1449, 1998.
210. Kudelka AP, Levy T, Verschraegen CF, et al: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3:1501-1505, 1997.
211. Sills AK Jr, Williams JI, Tyler BM, et al: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58:2784-2792, 1998.
212. Brem S, Wotoczek-Obadia, MC: Regulation of angiogenesis by copper reduction and penicillamine: Antagonism of cytokine and growth factor activity. AACR Special Conference: Angiogenesis and Cancer Research. 1998 (abstr).
213. Kerbel RS, Viloria-Petit A, Okada F, et al: Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286-295, 1998.
214. Arbiser JL, Moses MA, Fernandez CA, et al: Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94:861-866, 1997.
215. Shi YP, Ferrara N: Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). Biochem Biophys Res Comm 254:480-483, 1999.
216. Hahn SM, Bernhard EJ, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002.
217. Adjei AA, Erlichman C, Davis JN, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000.
218. Adjei AA, Mauer A, Bruzek L, et al: Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760-1766, 2003.
219. Brown PD: Clinical studies with matrix metalloproteinase inhibitors. APMIS 107:174-180, 1999.
220. Steward WP, Thomas AL: Marimastat: The clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 9:2913-2922, 2000.
221. Shou Y, Hirano T, Gong Y, et al: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 85:1706-1712, 2001.
222. Rha SY, Jeung HC, Roh JK, et al: Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Int J Mol Med 10:251-256, 2002.
223. Bodey B, Bodey B Jr, Siegel SE, et al: Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo 14:659-666, 2000.
224. Bonomi P: Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 29:78-86, 2002.
225. Shalinsky DR, Brekken J, Zou H, et al: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878:236-270, 1999.
226. Price A, Shi Q, Morris D, et al: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5:845-854, 1999.
227. Batist G, Patenaude F, Champagne P, et al: Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 13:1259-1263, 2002.
228. Gasparini G, Brooks PC, Biganzoli E, et al: Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin Cancer Res 4:2625-2634, 1998.
229. Gutheil JC, Campbell TN, Pierce PR, et al: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056-3061, 2000.
230. Posey JA, Khazaeli MB, DelGrosso A, et al: A pilot trial of Vitaxin, A humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132, 2001.
231. Kohn EC, Reed E, Sarosy G, et al: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996.
232. Kohn EC, Figg WD, Sarosy GA, et al: Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 15:1985-1993, 1997.
233. Stiles JD, Ostrow PT, Balos LL, et al: Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropath Exp Neurol 56:435-439, 1997.
234. Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949, 1995.
235. Bagnato A, Salani D, Di Castro V, et al: Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth. Cancer Res 59:720-727, 1999.
236. Shankar A, Loizidou M, Aliev G, et al: Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 85:502-506, 1998.
237. Carducci MA, Padley RJ, Breul J, et al: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-689, 2003.
238. Voest EE, Kenyon BM, O'Reilly MS, et al: Inhibition of angiogenesis in vivo by interleukin 12. J Nat Cancer Inst 87:581-586, 1995.
239. Cavallo F, Di Carlo E, Butera M, et al: Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59:414-421, 1999.
240. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441-1452, 1998.